1. Home
  2. GSIW vs RDHL Comparison

GSIW vs RDHL Comparison

Compare GSIW & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GSIW
  • RDHL
  • Stock Information
  • Founded
  • GSIW 2016
  • RDHL 2009
  • Country
  • GSIW Hong Kong
  • RDHL Israel
  • Employees
  • GSIW N/A
  • RDHL N/A
  • Industry
  • GSIW
  • RDHL Biotechnology: Pharmaceutical Preparations
  • Sector
  • GSIW
  • RDHL Health Care
  • Exchange
  • GSIW Nasdaq
  • RDHL Nasdaq
  • Market Cap
  • GSIW 12.3M
  • RDHL 8.2M
  • IPO Year
  • GSIW 2023
  • RDHL N/A
  • Fundamental
  • Price
  • GSIW $0.59
  • RDHL $5.58
  • Analyst Decision
  • GSIW
  • RDHL
  • Analyst Count
  • GSIW 0
  • RDHL 0
  • Target Price
  • GSIW N/A
  • RDHL N/A
  • AVG Volume (30 Days)
  • GSIW 11.5M
  • RDHL 10.4K
  • Earning Date
  • GSIW 12-31-2024
  • RDHL 04-07-2025
  • Dividend Yield
  • GSIW N/A
  • RDHL N/A
  • EPS Growth
  • GSIW N/A
  • RDHL N/A
  • EPS
  • GSIW N/A
  • RDHL N/A
  • Revenue
  • GSIW $1,313,795.00
  • RDHL $3,707,000.00
  • Revenue This Year
  • GSIW N/A
  • RDHL $224.90
  • Revenue Next Year
  • GSIW N/A
  • RDHL $82.69
  • P/E Ratio
  • GSIW N/A
  • RDHL N/A
  • Revenue Growth
  • GSIW N/A
  • RDHL N/A
  • 52 Week Low
  • GSIW $0.43
  • RDHL $5.41
  • 52 Week High
  • GSIW $15.45
  • RDHL $20.28
  • Technical
  • Relative Strength Index (RSI)
  • GSIW 49.76
  • RDHL 35.64
  • Support Level
  • GSIW $0.44
  • RDHL $5.50
  • Resistance Level
  • GSIW $1.25
  • RDHL $6.26
  • Average True Range (ATR)
  • GSIW 0.11
  • RDHL 0.32
  • MACD
  • GSIW 0.01
  • RDHL -0.02
  • Stochastic Oscillator
  • GSIW 18.62
  • RDHL 3.08

About GSIW Garden Stage Limited

Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.

About RDHL Redhill Biopharma Ltd.

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.

Share on Social Networks: